Endocrine Abstracts

Background: The NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional study (2006–2016), assessed the effectiveness and safety of real-life treatment with Norditropin®. Out of 20,548 enrolled patients, 20,195 (paediatric/adult; 17,711/2484) were included in the full analysis set (FAS) and 12,938 (11,967/971) in the effectiveness analysis set (EAS). Outcomes were assessed in children with growth hormone deficiency (...

Objectives: Congenital heart disease, especially pulmonary stenosis, is a frequent comorbidity in patients with Noonan syndrome (NS). Patients with NS are also at increased risk of childhood leukaemia and solid tumours. Among solid tumours, brain tumours, including glioneuronal tumours, have been described in younger patients but remain rare. Current safety data do not indicate an association of growth hormone (GH) therapy with increased risk for development or progression of ...

Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...

Introduction: Patients with AGHD receiving GH often have comorbidities requiring concomitant treatment. We evaluated patterns of concomitant medication use relative to GH therapy initiation in patients with AGHD.Methods: Patients with AGHD with data on concomitant medications enrolled in NordiNet® IOS (NCT00960128), an international, non-interventional study, receiving GH (Norditropin®, Novo Nordisk A/S, Denmark) therapy w...

Introduction: The clinical significance of the impact of GH on glucose homeostasis in adults with GH deficiency (GHD) remains unclear. We report the impact of 4 years of continuous GH therapy on HbA1c and progression to diabetes.Methods: Data were analysed from patients with adult-onset GHD (>20 years old) enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), an observational study, and treated with GH (Norditropin<su...

Background: Serum IGFI measurements are used during GH replacement in GHDA for titration of the GH dose, to monitor compliance and to avoid overdosing, but it is uncertain if pretreatment IGFI is a determinant of the GH dose or the response to GH treatment.Methods: Data from the NordiNet IOS have been analyzed to determine pretreatment serum IGFI concentrations in GHDA and to analyze if they influence the GH starting dose and/or the therapeutic response ...

Background: Data from several clinical studies have demonstrated the benefit of GH treatment in relation to bone mineral density and body composition in young adults who received GH treatment in childhood due to GHD1–3. There are recommendations to use a higher GH dose in the transition phase compared to the GH dose required during adulthood to mimic the endogenous GH secretion4,5.Methods: Data from NordiNet IOS have been analy...